Picture loading failed.

Pre-Made Selicrelumab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Selicrelumab (also known as RO 7009789, RG 7876) is a monoclonal antibody agonist of the cell surface receptor CD40, that is being developed by Roche for the treatment of solid tumours, B cell lymphomas and pancreatic cancer.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-511-1mg 1mg 3090
GMP-Bios-ab-511-10mg 10mg 21890
GMP-Bios-ab-511-100mg 100mg 148000
GMP-Bios-ab-511-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Selicrelumab biosimilar, Whole mAb, Anti-CD40 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5 therapeutic antibody
INN Name Selicrelumab
TargetCD40
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2017
CompaniesAbramson Cancer Center of the University of Pennsylvania;Roche
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development Techna